127 related articles for article (PubMed ID: 29091762)
1. TFCP2 Is Required for YAP-Dependent Transcription to Stimulate Liver Malignancy.
Zhang X; Sun F; Qiao Y; Zheng W; Liu Y; Chen Y; Wu Q; Liu X; Zhu G; Chen Y; Yu Y; Pan Q; Wang J
Cell Rep; 2017 Oct; 21(5):1227-1239. PubMed ID: 29091762
[TBL] [Abstract][Full Text] [Related]
2. CCT3 acts upstream of YAP and TFCP2 as a potential target and tumour biomarker in liver cancer.
Liu Y; Zhang X; Lin J; Chen Y; Qiao Y; Guo S; Yang Y; Zhu G; Pan Q; Wang J; Sun F
Cell Death Dis; 2019 Sep; 10(9):644. PubMed ID: 31501420
[TBL] [Abstract][Full Text] [Related]
3. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
[TBL] [Abstract][Full Text] [Related]
4. YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells.
Xia Y; Zhang YL; Yu C; Chang T; Fan HY
PLoS One; 2014; 9(11):e109575. PubMed ID: 25369529
[TBL] [Abstract][Full Text] [Related]
5. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.
Zhou Z; Hu T; Xu Z; Lin Z; Zhang Z; Feng T; Zhu L; Rong Y; Shen H; Luk JM; Zhang X; Qin N
FASEB J; 2015 Feb; 29(2):724-32. PubMed ID: 25384421
[TBL] [Abstract][Full Text] [Related]
6. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ.
Mesrouze Y; Meyerhofer M; Bokhovchuk F; Fontana P; Zimmermann C; Martin T; Delaunay C; Izaac A; Kallen J; Schmelzle T; Erdmann D; Chène P
Protein Sci; 2017 Dec; 26(12):2399-2409. PubMed ID: 28960584
[TBL] [Abstract][Full Text] [Related]
7. Mutual inhibition between YAP and SRSF1 maintains long non-coding RNA, Malat1-induced tumourigenesis in liver cancer.
Wang J; Wang H; Zhang Y; Zhen N; Zhang L; Qiao Y; Weng W; Liu X; Ma L; Xiao W; Yu W; Chu Q; Pan Q; Sun F
Cell Signal; 2014 May; 26(5):1048-59. PubMed ID: 24468535
[TBL] [Abstract][Full Text] [Related]
8. Dissection of the interaction between the intrinsically disordered YAP protein and the transcription factor TEAD.
Mesrouze Y; Bokhovchuk F; Meyerhofer M; Fontana P; Zimmermann C; Martin T; Delaunay C; Erdmann D; Schmelzle T; Chène P
Elife; 2017 Apr; 6():. PubMed ID: 28430104
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
[TBL] [Abstract][Full Text] [Related]
10. A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer.
Zhu C; Li L; Zhang Z; Bi M; Wang H; Su W; Hernandez K; Liu P; Chen J; Chen M; Huang TH; Chen L; Liu Z
Mol Cell; 2019 Aug; 75(4):791-806.e8. PubMed ID: 31303470
[TBL] [Abstract][Full Text] [Related]
11. TEA Domain Transcription Factor 4 Is the Major Mediator of Yes-Associated Protein Oncogenic Activity in Mouse and Human Hepatoblastoma.
Zhang J; Liu P; Tao J; Wang P; Zhang Y; Song X; Che L; Sumazin P; Ribback S; Kiss A; Schaff Z; Cigliano A; Dombrowski F; Cossu C; Pascale RM; Calvisi DF; Monga SP; Chen X
Am J Pathol; 2019 May; 189(5):1077-1090. PubMed ID: 30794805
[TBL] [Abstract][Full Text] [Related]
12. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3.
Jang JW; Kim MK; Lee YS; Lee JW; Kim DM; Song SH; Lee JY; Choi BY; Min B; Chi XZ; Bae SC
Oncogene; 2017 Feb; 36(7):999-1011. PubMed ID: 27425596
[TBL] [Abstract][Full Text] [Related]
13. YAP/TEAD-mediated transcription controls cellular senescence.
Xie Q; Chen J; Feng H; Peng S; Adams U; Bai Y; Huang L; Li J; Huang J; Meng S; Yuan Z
Cancer Res; 2013 Jun; 73(12):3615-24. PubMed ID: 23576552
[TBL] [Abstract][Full Text] [Related]
14. Structural and ligand-binding analysis of the YAP-binding domain of transcription factor TEAD4.
Li Y; Liu S; Ng EY; Li R; Poulsen A; Hill J; Pobbati AV; Hung AW; Hong W; Keller TH; Kang C
Biochem J; 2018 Jun; 475(12):2043-2055. PubMed ID: 29760238
[TBL] [Abstract][Full Text] [Related]
15. The oncoprotein HBXIP up-regulates YAP through activation of transcription factor c-Myb to promote growth of liver cancer.
Wang Y; Fang R; Cui M; Zhang W; Bai X; Wang H; Liu B; Zhang X; Ye L
Cancer Lett; 2017 Jan; 385():234-242. PubMed ID: 27765671
[TBL] [Abstract][Full Text] [Related]
16. Mutual interaction between YAP and CREB promotes tumorigenesis in liver cancer.
Wang J; Ma L; Weng W; Qiao Y; Zhang Y; He J; Wang H; Xiao W; Li L; Chu Q; Pan Q; Yu Y; Sun F
Hepatology; 2013 Sep; 58(3):1011-20. PubMed ID: 23532963
[TBL] [Abstract][Full Text] [Related]
17. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.
Wei H; Wang F; Wang Y; Li T; Xiu P; Zhong J; Sun X; Li J
Cancer Sci; 2017 Mar; 108(3):478-487. PubMed ID: 28002618
[TBL] [Abstract][Full Text] [Related]
18. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP.
Liu-Chittenden Y; Huang B; Shim JS; Chen Q; Lee SJ; Anders RA; Liu JO; Pan D
Genes Dev; 2012 Jun; 26(12):1300-5. PubMed ID: 22677547
[TBL] [Abstract][Full Text] [Related]
19. The membrane protein melanoma cell adhesion molecule (MCAM) is a novel tumor marker that stimulates tumorigenesis in hepatocellular carcinoma.
Wang J; Tang X; Weng W; Qiao Y; Lin J; Liu W; Liu R; Ma L; Yu W; Yu Y; Pan Q; Sun F
Oncogene; 2015 Nov; 34(47):5781-95. PubMed ID: 25728681
[TBL] [Abstract][Full Text] [Related]
20. A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator.
Yagi R; Chen LF; Shigesada K; Murakami Y; Ito Y
EMBO J; 1999 May; 18(9):2551-62. PubMed ID: 10228168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
